DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/nk5cpf/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Adienne Pharma & Biotech
- Alligator Bioscience AB
- Antipodean Pharmaceuticals, Inc.
- BioLineRx, Ltd.
- Biomedica Management Corporation
- Bolder Biotechnology, Inc.
- Catalyst Biosciences, Inc.
- Curatis Pharma GmbH
- Gilead Sciences, Inc.
- Ischemix
- LG Life Sciences, Ltd.
- Lotus Pharmaceutical Co., Ltd.
- Mercury Pharmaceuticals, Inc.
- Omeros Corporation
- Opsona Therapeutics Ltd.
- Peptinnovate Limited
- Pharming Group N.V.
- PledPharma AB
- Prolong Pharmaceuticals
- Proteo, Inc.
- Prothix BV
- Trophos SA
- Zealand Pharma A/S
- Zyrnat Biotherapeutics SL
Drug Profiles
- ADC-1004
- AM/AMBP-1
- ANV-6L15
- APP-103
- BBT-030
- BBT-045
- BL-7060
- C1 esterase inhibitor (recombinant)
- CB-2782
- CMX-2043
- CRX-526
- Curaglutide
- danegaptide
- Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury
- Drugs to Modulate NKT II Cells for Autoimmune, Gastrointestinal and Cardiovascular Disorders
- Elafin
- EP-80317
- Ergidina
- GS-459679
- KN-93
- KR-62980
- LSNTU-106
- mangafodipir
- MFH-244
- MG-53
- mirococept
- MitoQ
- Monoclonal Antibody for Ischemia Reperfusion Injury
- Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury
- Monoclonal Antibody to Inhibit IL-16 for Ischemia Reperfusion Injury
- MTP-131
- NBD Peptide
- NecX
- Neutrolide
- NOXD-21
For more information visit http://www.researchandmarkets.com/research/nk5cpf/ischemia
